Phase I Study of [14C]Zorifertinib Shows Promising Safety and Pharmacokinetics
[14C]Zorifertinib is undergoing Phase I study to evaluate its safety and pharmacokinetics in healthy males.
Asset / Drug
Drug and asset intelligence for Zorifertinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.